Natriuretic peptides are endogenous antagonists of vasoconstrictor and salt- and water-retaining systems in the body's defence against blood pressure elevation and plasma volume expansion, through direct vasodilator, diuretic and natriuretic properties. In addition, natriuretic peptides may play a role in the modulation of the molecular mechanisms involved in metabolic regulation and cardiovascular remodelling. The metabolic syndrome is characterized by visceral obesity, hyperlipidaemia, vascular inflammation and hypertension, which are linked by peripheral insulin resistance. Increased visceral adiposity may contribute to the reduction in the circulating levels of natriuretic peptides. The dysregulation of neurohormonal systems, including the renin-angiotensin and the natriuretic peptide systems, may in turn contribute to the development of insulin resistance in dysmetabolic patients. In obese subjects with the metabolic syndrome, reduced levels of natriuretic peptides may be involved in the development of hypertension, vascular inflammation and cardio vascular remodelling, and this may predispose to the development of cardiovascular disease. The present review summarizes the regulation and function of the natriuretic peptide system in obese patients with the metabolic syndrome and the involvement of altered bioactive levels of natriuretic peptides in the pathophysiology of cardiovascular disease in patients with metabolic abnormalities.

Natriuretic peptides and cardiovascular damage in the metabolic syndrome. Molecular mechanisms and clinical implications / Savoia, Carmine; Volpe, Massimo; Alonzo, Alessandro; Rossi, C; Rubattu, Speranza Donatella. - In: CLINICAL SCIENCE. - ISSN 0143-5221. - STAMPA. - 118:4(2010), pp. 231-240. [10.1042/CS20090204]

Natriuretic peptides and cardiovascular damage in the metabolic syndrome. Molecular mechanisms and clinical implications

SAVOIA, Carmine;VOLPE, Massimo;ALONZO, ALESSANDRO;RUBATTU, Speranza Donatella
2010

Abstract

Natriuretic peptides are endogenous antagonists of vasoconstrictor and salt- and water-retaining systems in the body's defence against blood pressure elevation and plasma volume expansion, through direct vasodilator, diuretic and natriuretic properties. In addition, natriuretic peptides may play a role in the modulation of the molecular mechanisms involved in metabolic regulation and cardiovascular remodelling. The metabolic syndrome is characterized by visceral obesity, hyperlipidaemia, vascular inflammation and hypertension, which are linked by peripheral insulin resistance. Increased visceral adiposity may contribute to the reduction in the circulating levels of natriuretic peptides. The dysregulation of neurohormonal systems, including the renin-angiotensin and the natriuretic peptide systems, may in turn contribute to the development of insulin resistance in dysmetabolic patients. In obese subjects with the metabolic syndrome, reduced levels of natriuretic peptides may be involved in the development of hypertension, vascular inflammation and cardio vascular remodelling, and this may predispose to the development of cardiovascular disease. The present review summarizes the regulation and function of the natriuretic peptide system in obese patients with the metabolic syndrome and the involvement of altered bioactive levels of natriuretic peptides in the pathophysiology of cardiovascular disease in patients with metabolic abnormalities.
2010
natriuretic peptides; cardiovascular disease; metabolic syndrome; obesity; remodelling; renin-angiotensin system
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Natriuretic peptides and cardiovascular damage in the metabolic syndrome. Molecular mechanisms and clinical implications / Savoia, Carmine; Volpe, Massimo; Alonzo, Alessandro; Rossi, C; Rubattu, Speranza Donatella. - In: CLINICAL SCIENCE. - ISSN 0143-5221. - STAMPA. - 118:4(2010), pp. 231-240. [10.1042/CS20090204]
File allegati a questo prodotto
File Dimensione Formato  
Savoia_Natriuretic_2010.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 262.79 kB
Formato Adobe PDF
262.79 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/415852
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 23
social impact